"We are very excited that Mr. Handley, Mr. Ruud and Mr. Coder have agreed to serve on our board," said Ziemann. "As we move forward with our first commercial product, their life science and business experiences will add tremendous value and bring great insights to the company."
Michael K. Handley. Mr. Handley joined CHD as vice president of business development and regulatory affairs in 2012 and was promoted to chief executive officer in December of that same year. He has over 20 years of multifunctional management experience in the life science industry, including drug and device commercialization, regulatory affairs and quality, operations, business development, mergers and acquisitions, partnering, licensing, and research.
Prior to joining CHD, he served in senior positions for Vessix Vascular, Johnson and Johnson, Spectranetics, Accelapure and PRTM, were he advised Genentech as well as other large multi-national pharmaceutical companies.
Mr. Handley has also served as an advisor or board member for several small life science companies, including Reven Pharmaceuticals of Golden Colorado.
Mr. Handley began his career as a research scientist at Amgen. He received a Bachelor of Science degree in molecular biology and exercise physiology with minors in chemistry and neurobiology from Colorado State University in 1995. He also attended the Executive MBA program at Pepperdine University. He is a native of Colorado.
Alan J. Ruud. Mr. Ruud began his career in electrical consulting and found his first company, SPI Lighting, in 1975. He later sold the company and, in 1982, founded Ruud Lighting, a worldwide direct marketer of industrial and commercial lighting fixtures.
He served as chairman and CEO of the company while creating successful brands that are dedicated to the emerging use of LED technology for lighting applications. He sold Ruud Lighting to CREE in 2011 and served on their board through late 2015. He continues to serve as an advisor to CREE. Mr. Ruud is nationally recognized for his expertise in the lighting industry and has been awarded over 100 patents for innovative designs. He has received numerous awards for innovation, marketing, entrepreneurship and public service.
In 2015, the Ruud family purchased controlling interest in Deltahawk engines, a developer of multi-fuel aviation engines, where Mr. Ruud serves as chairman of the board.
He is a native of Wisconsin and received his Bachelor of Science degree in electrical engineering and an honorary doctorate from the Milwaukee School of Engineering. He has an MBA degree from the University of Chicago.
Steve Coder. Mr. Coder is currently president and co-founder of an e-commerce company launched in 2014. Previously, Mr. Coder was president, and CEO and director of Mayline, a manufacturer and distributor of mid-market office furniture.
Earlier in his career he served in senior executive roles within the HON company, the largest of HNI's operating companies. Roles included division president of two business units, and vice president and controller for the HON Company, a $1.2 billion enterprise.
Mr. Coder began his career as an auditor with Ernst and Whinney in Chicago. He received a bachelor of science in industrial administration from Iowa State University and is a CPA. He is a native of Muscatine, Iowa.
The Ruud and Coder families are major investors in CHD Bioscience.
Resigning from the board is Dr. Catherine Angell Sohn, an accomplished international pharmaceutical executive who will continue serving CHD senior management and the board of directors as a senior advisor.
Retiring from the board is Mr. Douglas Coder. Mr. Coder is one of the original directors and investors in the company and is retiring due to health reasons.
About CHD Bioscience
CHD Bioscience is a leading developer of products for topical and soft tissue infectious disease, with a focus in the orthopedic, surgical and wound care markets. CHD's mission is to become a leader in discovering, developing and bringing to market products that prevent and treat infectious disease in humans and animals in both industrialized and developing nations. The company applied to the FDA for its first commercial product, a coated orthopedic implant, in December 2015, and is awaiting approval.
Photos: (Click photo to enlarge)
Read Full Story - CHD Bioscience announces new directors to its board | More news from this source
Press release distribution by PRLog
